You just read:

EMA Validates Daiichi Sankyo's Marketing Authorization Application for Pexidartinib for Treatment of Patients with TGCT, a Rare, Debilitating, Non-Malignant Tumor

News provided by

Daiichi Sankyo Company, Limited

03 Apr, 2019, 13:03 BST